Home / Investors / Financial information

Financial information

More financial information about PEPTONIC medical is available on spotlightstockmarket.com.

Financial calendar 2022

Financial event Date
Year end report 2021 February 25th 2022
Annual report 2021 February 28th 2022
Quarterly report 1 May 12th 2022
Annual General Meeting May 24th 2022
Quarterly report 2 August 18th 2022
Quarterly report 3 November 10th 2022
Year end report, 2022 February 24th 2023

Financial reports

pdf_symbol_35px  Annual report 2021 (Swedish)
pdf_symbol_35px Annual report 2020 (Swedish)
pdf_symbol_35px Annual report 2019 (Swedish)
pdf_symbol_35px  Annual report 2018 (Swedish)
pdf_symbol_35px Annual report 2017 (Swedish)
pdf_symbol_35px Annual report 2016 (Swedish)
pdf_symbol_35px Annual report 2015 (English)
pdf_symbol_35px Annual report 2015 (Swedish)
pdf_symbol_35px Annual report 2014 (Swedish)
pdf_symbol_35px Annual report 2013 (Swedish)
pdf_symbol_35px Annual report 2012 (Swedish)
pdf_symbol_35px Annual report 2011 (Swedish)
pdf_symbol_35px Annual report 2010 (Swedish)
 

Recent Comments

    All press releases on Spotlightstockmarket.com

    All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

    About us

    PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

    The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

    Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.